Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 16 citing articles:

Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis
Cristina Bezzio, Marta Vernero, Davide Giuseppe Ribaldone, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2197-2197
Open Access | Times Cited: 18
Temporal Trends in the Use of Biological Agents in Patients with Inflammatory Bowel Disease: Real-World Data from a Tertiary Inflammatory Bowel Disease Greek Center During a 5-Year Period
Panagiotis Markopoulos, Aikaterini Gaki, Georgios Kokkotis, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1357-1357
Open Access
Assessing the economics of biologic and small molecule therapies for the treatment of moderate to severe ulcerative colitis in Japan: a cost per responder analysis of upadacitinib
Masayuki Saruta, Isao Kawaguchi, Y OGAWA, et al.
Journal of Medical Economics (2024) Vol. 27, Iss. 1, pp. 566-574
Open Access | Times Cited: 3
Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn’s Disease: A Review of Comparative Effectiveness Studies
Mohmmed Sharip, Nilanga Nishad, Lushen Pillay, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 8, pp. 2187-2187
Open Access | Times Cited: 3
Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease
Mahmoud Mosli, Hajer Almudaiheem, Turki AlAmeel, et al.
Saudi Journal of Gastroenterology (2022) Vol. 29, Iss. Suppl 1, pp. S1-S35
Open Access | Times Cited: 12
Efficacy of Second-Line Biological Therapies in Moderate to Severe Ulcerative Colitis Patients with Prior Failure of Anti-Tumor Necrosis Factor Therapy: A Multi-Center Study
Ji-Eun Na, Yong-Eun Park, Jongha Park, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 10, pp. 1066-1066
Open Access | Times Cited: 2
Systematic Review and Meta-Analysis of Observational Studies on the Effectiveness and Safety of Ustekinumab among Patients with Inflammatory Bowel Disease in Eastern and Western Countries
He Zhou, Fang Wang, Jian Wan, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 5, pp. 1894-1894
Open Access | Times Cited: 6
Short term effectiveness of ustekinumab versus vedolizumab in Crohn’s disease after failure of anti-TNF agents: An observational comparative study design with a Bayesian analysis
Ahmad Alamer, Lina H Al Lehaibi, Mukhtar Alomar, et al.
Saudi Journal of Gastroenterology (2024) Vol. 30, Iss. 5, pp. 324-334
Open Access | Times Cited: 1
Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review
Peter M. Irving, Peter Hur, Raju Gautam, et al.
Journal of Managed Care & Specialty Pharmacy (2024) Vol. 30, Iss. 9, pp. 1026-1040
Closed Access | Times Cited: 1
FORWARD: A Learning Framework for Logical Network Perturbations to Prioritize Targets for Drug Development
Saptarshi Sinha, Ella McLaren, Madhubanti Mullick, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Effectiveness of tofacitinib in patients with ulcerative colitis: an updated systematic review and meta-analysis of real-world studies
Chien-Hung Lin, Wei Liu, Chuan Wan, et al.
BMJ Open Gastroenterology (2024) Vol. 11, Iss. 1, pp. e001347-e001347
Open Access | Times Cited: 1
Vedolizumab versus ustekinumab in Crohn’s disease with prior anti-tumor necrosis factor failure: an updated meta-analysis
Natália Junkes Milioli, Matheus Vanzin Fernandes, Tulio Loyola Correa, et al.
European Journal of Gastroenterology & Hepatology (2024) Vol. 36, Iss. 9, pp. 1068-1074
Closed Access
IBD Patients with Primary or Secondary Nonresponse to Ustekinumab Benefit from Dose Escalation or Reinduction
Filippo Vernia, Sabrina Monaco, Giovanni Latella
Journal of Clinical Medicine (2024) Vol. 13, Iss. 14, pp. 3993-3993
Open Access
Long-term efficacy and survival of ustekinumab therapy in patients with inflammatory bowel disease
М. В. Шапина
Meditsinskiy sovet = Medical Council (2024), Iss. 15, pp. 166-172
Open Access
Superior persistence of ustekinumab compared to anti-TNF in vedolizumab-experienced inflammatory bowel diseases patients: a real-world cohort study
Horng-Yih Chiu, Chia‐Jung Kuo, Ming‐Wei Lai, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access
CRP/Albumin Ratio as Potential Indicator for Assessment of Disease Activity in Inflammatory Bowel Disease Patients
Faheez Mohamed, Eman R. Youness, Mona Hassan, et al.
Biomedical & Pharmacology Journal (2024) Vol. 17, Iss. 4, pp. 2683-2692
Open Access
Page 1

Scroll to top